scispace - formally typeset
S

Sue Cammarata

Researcher at Pharmacia

Publications -  55
Citations -  2460

Sue Cammarata is an academic researcher from Pharmacia. The author has contributed to research in topics: Delafloxacin & Vancomycin. The author has an hindex of 20, co-authored 54 publications receiving 2249 citations. Previous affiliations of Sue Cammarata include Henry Ford Hospital & Michigan State University.

Papers
More filters
Journal ArticleDOI

Linezolid vs Vancomycin: Analysis of Two Double-Blind Studies of Patients With Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia

Richard G. Wunderink, +4 more
- 01 Nov 2003 - 
TL;DR: In this article, the effect of baseline variables, including treatment, on outcome in patients with nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) was assessed by survival and clinical cure rates.
Journal ArticleDOI

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.

Ethan Rubinstein, +3 more
- 01 Feb 2001 - 
TL;DR: Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia and Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups.
Journal ArticleDOI

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

Richard G. Wunderink, +3 more
- 01 Mar 2003 - 
TL;DR: In the population studied, linezolid appeared to be as well tolerated and as effective as vancomycin, each in combination with aztreonam.
Journal ArticleDOI

Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies

Ethan Rubinstein, +8 more
- 01 Jun 2003 - 
TL;DR: The risk for transient, reversible hematologic effects from treatment with linezolid should be considered together with the clinical benefits associated with its use.
Journal ArticleDOI

A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections

William O'Riordan, +5 more
- 01 Jan 2015 - 
TL;DR: Overall, the most frequent adverse events were nausea, vomiting, and diarrhea; the 300-mg delafloxacin arm was the best-tolerated regimen.